ViroGates A/S (OCSE:VIRO) EV-to-EBIT : -2.87 (As of May. 11, 2024)

View and export this data going back to 2018. Start your Free Trial

What is ViroGates A/S EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ViroGates A/S's Enterprise Value is kr37.16 Mil. ViroGates A/S's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-12.96 Mil. Therefore, ViroGates A/S's EV-to-EBIT for today is -2.87.

The historical rank and industry rank for ViroGates A/S's EV-to-EBIT or its related term are showing as below:

OCSE:VIRO' s EV-to-EBIT Range Over the Past 10 Years
Min: -39.24 Med: -7.59 Max: -2.23
Current: -2.87

During the past 8 years, the highest EV-to-EBIT of ViroGates A/S was -2.23. The lowest was -39.24. And the median was -7.59.

OCSE:VIRO's EV-to-EBIT is ranked worse than
100% of 455 companies
in the Medical Devices & Instruments industry
Industry Median: 20.82 vs OCSE:VIRO: -2.87

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ViroGates A/S's Enterprise Value for the quarter that ended in Mar. 2024 was kr34.96 Mil. ViroGates A/S's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-12.96 Mil. ViroGates A/S's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -37.07%.

ViroGates A/S EV-to-EBIT Historical Data

The historical data trend for ViroGates A/S's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViroGates A/S EV-to-EBIT Chart

ViroGates A/S Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-3.18

-11.22

-23.51

-11.55

-2.24

ViroGates A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-14.24	-5.30	-6.17	-2.24	-2.70

Competitive Comparison of ViroGates A/S's EV-to-EBIT

For the Medical Devices subindustry, ViroGates A/S's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ViroGates A/S's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ViroGates A/S's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ViroGates A/S's EV-to-EBIT falls into.

ViroGates A/S EV-to-EBIT Calculation

ViroGates A/S's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	37.155	/	-12.961
	=	-2.87

ViroGates A/S's current Enterprise Value is kr37.16 Mil.
ViroGates A/S's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-12.96 Mil.

ViroGates A/S (OCSE:VIRO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ViroGates A/S's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-12.961	/	34.963305
	=	-37.07 %

ViroGates A/S's Enterprise Value for the quarter that ended in Mar. 2024 was kr34.96 Mil.
ViroGates A/S's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-12.96 Mil.

ViroGates A/S EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ViroGates A/S's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

ViroGates A/S (OCSE:VIRO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViroGates A/S (OCSE:VIRO) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Banevaenget 13, Birkerod, DNK, DK-3460

Website

https://www.virogates.com

ViroGates A/S is a life science company that develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular, to make a clinical decision on hospitalization or discharge of emergency patients. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, and cancer. It has developed a product line called suPARnostic to make the suPAR test available as a commercially available test and the ambition is to get the test implemented and used for clinical decision-making.

ViroGates A/S (OCSE:VIRO) Headlines

No Headlines